Medication info

Idalbi Clopidogrel Tablet 40/25 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Potassium Azilsartan Medoxomil›42.68mg / 1 tabletChlorthalidone›25mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Inc.
Appearance
Bright red, double convex, round film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2), 56 tablets (14 tablets/PTP X 4)
Approval status
Approval withdrawn

MFDS item code 201803208 · Approved 2018.08.06 · Insurance code 693903540

This product's status changed to Approval withdrawn on 2024.05.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension and stage 2 hypertension
Who takes it
Adults · Children
Adult dose
1. Adults The recommended initial dose of this drug is 40/12.5 milligrams, taken with water, regardless of meals. The antihypertensive effect is evident in most patients within 1-2 weeks. If blood pressure control is needed after 2-4 weeks, the dose may be increased to 40/25 milligrams. Doses exceeding 40/25 milligrams are not useful. 1) Patients whose blood pressure is not adequately controlled with monotherapy: It is recommended that the dose of azilsartan medoxomil be adjusted before this drug is administered. For patients whose blood pressure is not adequately controlled with azilsartan medoxomil monotherapy, switching to this drug may be considered. The recommended initial dose is 40/12.5 milligrams once daily. 2) When this drug is administered as initial therapy to patients with stage 2 hypertension, the decision should be based on an assessment of the potential benefits and risks, including whether the patient is likely to tolerate the initial dose. The recommended initial dose is 40/12.5 milligrams once daily. 2. Elderly patients No dose adjustment is necessary when this drug is administered to elderly patients. Although no overall differences in safety or efficacy were observed between elderly and younger patients, greater sensitivity in some elderly patients cannot be ruled out. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. 4. Patients with hepatic impairment Experience with the use of this drug is limited; however, based on clinical results with azilsartan medoxomil, no dose adjustment is necessary in patients with mild or moderate hepatic impairment. 5. Patients with intravascular volume depletion In patients with salt depletion or who may have volume depletion (e.g., patients with vomiting or diarrhea, or those receiving high doses of diuretics), correct the volume status before initiating this drug and begin treatment under close medical supervision.
Child dose
The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Ingredients

Importer
Celltrion Pharm, Inc.

Efficacy & effects

Treatment of essential hypertension and stage 2 hypertension

  • Essential hypertension
  • stage 2 hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by azilsartan medoxomil monotherapy, and for patients with stage 2 hypertension who require combination therapy to reach their target blood pressure. In other words, this medication helps to effectively control blood pressure in various types of hypertension treatment.

How to take

Adult dose

1. Adults The recommended initial dose of this drug is 40/12.5 milligrams, taken with water, regardless of meals. The antihypertensive effect is evident in most patients within 1-2 weeks. If blood pressure control is needed after 2-4 weeks, the dose may be increased to 40/25 milligrams. Doses exceeding 40/25 milligrams are not useful. 1) Patients whose blood pressure is not adequately controlled with monotherapy: It is recommended that the dose of azilsartan medoxomil be adjusted before this drug is administered. For patients whose blood pressure is not adequately controlled with azilsartan medoxomil monotherapy, switching to this drug may be considered. The recommended initial dose is 40/12.5 milligrams once daily. 2) When this drug is administered as initial therapy to patients with stage 2 hypertension, the decision should be based on an assessment of the potential benefits and risks, including whether the patient is likely to tolerate the initial dose. The recommended initial dose is 40/12.5 milligrams once daily. 2. Elderly patients No dose adjustment is necessary when this drug is administered to elderly patients. Although no overall differences in safety or efficacy were observed between elderly and younger patients, greater sensitivity in some elderly patients cannot be ruled out. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. 4. Patients with hepatic impairment Experience with the use of this drug is limited; however, based on clinical results with azilsartan medoxomil, no dose adjustment is necessary in patients with mild or moderate hepatic impairment. 5. Patients with intravascular volume depletion In patients with salt depletion or who may have volume depletion (e.g., patients with vomiting or diarrhea, or those receiving high doses of diuretics), correct the volume status before initiating this drug and begin treatment under close medical supervision.

Child dose

The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with impaired liver function or advanced liver disease may experience fluid and electrolyte imbalances while taking this medication, leading to serious issues such as hepatic coma. Caution is advised for patients with severe kidney disease, as this medication’s diuretic component may induce hyperazotemia. Patients with allergies to this medication or its components, pregnant or breastfeeding women, anuria patients, and those with severe liver or kidney dysfunction should not take this medication. Patients with low blood volume or salt deficiency may experience hypotension; hence, conditions should be corrected before administration, and if hypotension occurs, they should lie down and receive intravenous fluids if necessary. Patients with decreased kidney function must be regularly monitored for worsening kidney function during treatment, and discontinuation may be necessary if the condition worsens. The safety of this medication has not been established in patients with severely impaired liver function, so its use is not recommended. This medication may cause electrolyte imbalances, particularly hyponatremia and hypokalemia, so electrolyte levels should be regularly monitored through blood tests. Caution is necessary for patients with a history of hyperuricemia or gout, as symptoms may worsen during use. Concurrent use with other renin-angiotensin-aldosterone system (RAAS) acting medications may increase the risk of hypotension, hyperkalemia, and kidney dysfunction, so combination should be avoided. Elderly patients and those with cardiovascular disease or certain heart valve diseases also require special attention when taking this medication. Dizziness or drowsiness may occur during treatment, so caution is advised when driving or operating hazardous machinery. There may be interactions when used with lithium, non-steroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, etc., so consulting with a doctor or pharmacist is essential. Use of this medication during pregnancy or breastfeeding is not recommended, especially during lactation, since the ingredients may be transmitted through breast milk and pose risks to the newborn. In case of overdose, symptoms such as hypotension, dizziness, and electrolyte imbalances may occur, necessitating immediate medical attention. This medication should be kept out of reach of children and stored in its original packaging, away from light and moisture.

Side effects

  • Increased serum creatinine
  • headache
  • dizziness
  • orthostatic dizziness
  • syncope
  • paresthesia
  • hypotension
  • diarrhea
  • nausea
  • vomiting
Show 68 more
  • rash
  • pruritus
  • muscle cramps
  • fatigue
  • anemia
  • increased serum uric acid
  • hyperuricemia
  • hypokalemia
  • increased serum potassium
  • hyponatremia
  • decreased serum sodium
  • peripheral edema
  • migraine
  • increased serum creatine phosphokinase
  • renal dysfunction
  • angioedema
  • thrombocytopenia
  • leukopenia
  • agranulocytosis
  • eosinophilia
  • increased serum lipids
  • hypomagnesemia
  • hypercalcemia
  • diabetes
  • worsening of diabetic metabolic state
  • hypochloremic alkalosis
  • headache
  • orthostatic hypotension
  • cardiac arrhythmias
  • idiopathic pulmonary edema
  • loss of appetite
  • mild gastrointestinal disturbances
  • constipation
  • abdominal pain
  • pancreatitis
  • intrahepatic bile acid stasis
  • jaundice
  • urticaria
  • phototoxic reactions
  • skin vasculitis
  • allergic interstitial nephritis
  • weakness
  • renal impairment
  • renal failure
  • increased serum triglycerides
  • tremor
  • hyperkalemia
  • palpitations
  • constipation
  • foul breath
  • dyspnea
  • joint pain
  • myalgia
  • musculoskeletal rigidity
  • vascular disorders
  • exacerbation of hypertension
  • chest pain
  • palpitations
  • dizziness
  • syncope
  • total syncope
  • weakness
  • dyspnea
  • subdural hemorrhage
  • irregular menstruation
  • worsening of blood pressure
  • increased serum triglycerides
  • tremor

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container protected from light, at room temperatures between 1 degree Celsius and 30 degrees Celsius. Additionally, it should be kept in a manner that prevents exposure to moisture.

Appearance and packaging

Appearance

Bright red, double convex, round film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2), 56 tablets (14 tablets/PTP X 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.